Standout Papers
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial (2023)
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial (2021)
Citation Impact
4 from Science/Nature 58 standout
Citing Papers
Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
2024 Standout
Adipose tissue retains an epigenetic memory of obesity after weight loss
2024 StandoutNature
Works of Lars Erichsen being referenced
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
2023 Standout
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
2021 Standout
Author Peers
| Author | Molecular Biology | EDM | Surgery | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|
| Lars Erichsen | 274 | 516 | 261 | 43 | 962 | |
| C. G. Guttridge | 161 | 1 | 33 | 709 | ||
| J P Guastalla | 72 | 3 | 37 | 15 | 318 | |
| George J. Aulisio | 8 | 201 | ||||
| Barbara Polischi | 269 | 11 | 4 | 21 | 724 | |
| F.Q. Guo | 1 | 18 | 980 |
All Works
Login with ORCID to disown or claim papers
Loading papers...